Financial results & presentations

Together, the companies will produce highly sought-after, sweet-tasting molecules, such as steviol glycosides Reb M and Reb D through fermentation, giving food and beverage manufacturers an even more scalable, sustainable and low cost-in-use solution than if these same molecules were extracted from the stevia leaf.

08 Nov 2018

Sale of Fibrant’s caprolactam business to Highsun completed with DSM anticipating receiving about €200 million in cash related to this transaction, which is expected to be received in various steps in 2018 and 2019.

30 Oct 2018

DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.

09 Oct 2018

DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.

02 Oct 2018

DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.

25 Sep 2018

DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.

18 Sep 2018

DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.

13 Sep 2018

DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.

11 Sep 2018

DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.

04 Sep 2018

DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.

28 Aug 2018

DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.

21 Aug 2018

DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.

13 Aug 2018

Investment builds on the previously announced partnership between DSM and Mixfit and combines DSM’s unparalleled expertise in essential micronutrients with the technological edge of Mixfit to analyze health data in real-time, address nutritional gaps in an effective way and supporting a healthy lifestyle.

02 Jul 2018

Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.

29 Jun 2018

DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.

22 Jun 2018

With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.

20 Jun 2018

DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.

15 Jun 2018

DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.

12 Jun 2018

DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.

01 Jun 2018

DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.

30 May 2018

DSM has linked the interest rate of new €1 billion Revolving Credit Facility to its performance on the reduction of GHG emissions.

30 May 2018

DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.

18 May 2018

DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.

18 May 2018

DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.

09 May 2018

DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.

09 May 2018

Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.

08 May 2018

DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.

13 Apr 2018

Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.

12 Apr 2018

DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.

06 Apr 2018

DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.

30 Mar 2018

DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.

23 Mar 2018

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.

19 Mar 2018

The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.

01 Mar 2018

DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.

14 Feb 2018

Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.

29 Dec 2017

DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.

22 Dec 2017

DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

17 Nov 2017

DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.

17 Nov 2017

DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.

10 Nov 2017

Strong performance in Q3 2017, contributing to very good first nine months.

02 Nov 2017

DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.

09 Oct 2017

DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.

06 Oct 2017

DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.

29 Sep 2017

EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.

25 Sep 2017

DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.

22 Sep 2017

Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.

22 Sep 2017

DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.

15 Sep 2017

DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.

08 Sep 2017

DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.

07 Sep 2017

DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.

01 Sep 2017

Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.

29 Aug 2017

DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.

25 Aug 2017

DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.

18 Aug 2017

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.

14 Aug 2017

DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.

01 Aug 2017

Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.

21 Jul 2017

DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.

14 Jul 2017

DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.

07 Jul 2017

DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.

30 Jun 2017

DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.

23 Jun 2017

DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.

16 Jun 2017

DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.

09 Jun 2017

DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.

02 Jun 2017

DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.

26 May 2017

DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.

19 May 2017

Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.

15 May 2017

DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.

12 May 2017

DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.

08 May 2017

DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.

05 May 2017

DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.

03 May 2017

DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.

03 May 2017

DSM reports a very strong first quarter in 2017.

02 May 2017

DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.

28 Apr 2017

DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.

21 Apr 2017

DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.

14 Apr 2017

DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.

07 Apr 2017

DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.

31 Mar 2017

DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.

24 Mar 2017

DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.

21 Mar 2017

DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.

17 Mar 2017

DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.

13 Mar 2017

2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.

03 Mar 2017

DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.

15 Feb 2017

DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.

14 Feb 2017

DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.

09 Dec 2016

DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.

02 Dec 2016

DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.

25 Nov 2016

DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.

22 Nov 2016

DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.

18 Nov 2016

DSM reports another strong quarter in Q3 2016.

12 Nov 2016

DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.

11 Nov 2016

DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.

04 Nov 2016

DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.

19 Sep 2016

DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.

08 Sep 2016

DSM reports a second consecutive strong quarter in 2016.

02 Aug 2016

DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.

27 Jul 2016

DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.

22 Jul 2016

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.

21 Jul 2016

DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.

15 Jul 2016

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.

11 Jul 2016

DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.

08 Jul 2016

DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.

01 Jul 2016

DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.

24 Jun 2016

DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.

17 Jun 2016

DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.

10 Jun 2016

DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.

03 Jun 2016

DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26

27 May 2016

DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.

20 May 2016

DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.

13 May 2016

DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.

06 May 2016

DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.

03 May 2016

DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.

29 Apr 2016

DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.

29 Apr 2016

DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.

29 Apr 2016

DSM reports a strong first quarter in 2016.

26 Apr 2016

DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.

22 Apr 2016

DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.

15 Apr 2016

DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.

08 Apr 2016

DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.

01 Apr 2016

All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.

31 Mar 2016

DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.

25 Mar 2016

DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.

18 Mar 2016

DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.

11 Mar 2016

DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.

04 Mar 2016

DSM announces the publication of its 2015 Integrated Annual Report.

01 Mar 2016

DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.

26 Feb 2016

Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.

25 Feb 2016

DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.

22 Feb 2016

Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.

17 Feb 2016

At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.

07 Jan 2016

DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.

06 Nov 2015

After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.

04 Nov 2015

Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.

03 Nov 2015

DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.

30 Oct 2015

DSM successfully issued a €500 million 1.375% bond due 2022.

15 Sep 2015

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.

10 Sep 2015

Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.

25 Aug 2015

Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.

04 Aug 2015

Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..

31 Jul 2015

DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.

29 Jul 2015

DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.

24 Jul 2015

DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.

17 Jul 2015

DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.

10 Jul 2015

DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.

03 Jul 2015

DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.

26 Jun 2015

DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.

19 Jun 2015

DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.

12 Jun 2015

DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.

05 Jun 2015

DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.

29 May 2015

DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.

22 May 2015

DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.

14 May 2015

DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.

30 Apr 2015

DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.

30 Apr 2015

Sales of €1,886 million, up 11%, including 2% organic sales growth.

29 Apr 2015

DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.

02 Apr 2015

Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.

02 Apr 2015

DSM has successfully issued a €500 million 1.0% bond due 2025.

01 Apr 2015

DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.

31 Mar 2015

DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.

18 Mar 2015

Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.

16 Mar 2015

Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.

03 Mar 2015

DSM announces publication of 2014 Integrated Annual Report.

03 Mar 2015

Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.

11 Feb 2015

DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.

23 Dec 2014

DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.

17 Dec 2014

DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.

05 Nov 2014

Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.

04 Nov 2014

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.

11 Sep 2014

POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.

03 Sep 2014

DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.

05 Aug 2014

DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.

11 Jul 2014

Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.

02 Jul 2014

DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.

20 May 2014

DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.

16 May 2014

DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.

09 May 2014

DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.

07 May 2014

DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.

07 May 2014

DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.

06 May 2014

DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.

02 May 2014

DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.

25 Apr 2014

DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.

18 Apr 2014

DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.

11 Apr 2014

DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.

09 Apr 2014

DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.

04 Apr 2014

DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.

28 Mar 2014

DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.

21 Mar 2014

DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.

14 Mar 2014

USD 2.65 billion transaction to create global CDMO leader successfully completed.

11 Mar 2014

DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.

10 Mar 2014

DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.

07 Mar 2014

DSM issues €500 million 2.375% bond due 2024.

28 Feb 2014

DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

27 Feb 2014

For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.

26 Feb 2014

DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.

23 Jan 2014

DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.

21 Jan 2014

DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.

17 Jan 2014

DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.

10 Jan 2014

DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.

20 Dec 2013

Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.

18 Dec 2013

DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.

13 Dec 2013

DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.

06 Dec 2013

DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.

21 Nov 2013

DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.

21 Nov 2013

Global CDMO company combines DSM Pharmaceutical Products and Patheon.

19 Nov 2013

DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.

15 Nov 2013

DSM successfully issues €300 million 1.75% bond due 2019.

06 Nov 2013

DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

06 Nov 2013

Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.

05 Nov 2013

DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.

09 Oct 2013

DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.

26 Sep 2013

DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.

12 Sep 2013

DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.

06 Aug 2013

DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.

01 Jul 2013

Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.

07 May 2013

DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.

03 May 2013

DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.

03 May 2013

DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.

02 May 2013

Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.

08 Apr 2013

Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.

08 Apr 2013

DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.

08 Apr 2013

DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.

14 Mar 2013

DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.

04 Mar 2013

DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.

20 Feb 2013

Completing acquisition of Fortitech is another milestone in implementation of DSM’s Nutrition strategy.

19 Dec 2012

Acquisition enables DSM to become a global tier one dairy ingredients supplier.

06 Dec 2012

DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.

23 Nov 2012

Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.

12 Nov 2012

Definitive agreement to acquire Fortitech, Inc. (Fortitech) in an all cash transaction for a total enterprise value of $634 million.

08 Nov 2012

DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.

06 Nov 2012

DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.

26 Oct 2012

DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.

27 Sep 2012

Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.

20 Sep 2012

DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.

20 Sep 2012

DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.

13 Sep 2012

Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.

08 Aug 2012

Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.

07 Aug 2012

DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.

19 Jul 2012

DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.

25 Jun 2012

Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.

19 Jun 2012

Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.

06 Jun 2012

DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.

05 Jun 2012

DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.

21 May 2012

Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.

18 May 2012

Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

11 May 2012

DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.

11 May 2012

DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.

11 May 2012

In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.

08 May 2012

DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.

03 May 2012

Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.

01 May 2012

DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.

26 Mar 2012

2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.

29 Feb 2012

Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.

14 Feb 2012

Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.

23 Jan 2012

DSM Supervisory Board proposes appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

11 May 2012

Q3 2011 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010, outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving 2013 targets.

26 Nov 2011

DSM repurchased 502,990 shares from 27 October to 2 November 2011 at an average price of €37.33 and concluded the program to repurchase 4,000,000 shares.

03 Nov 2011

DSM repurchased 471,588 shares from 20 to 26 October 2011 at an average price of €36.81.

27 Oct 2011

TCG has developed and patented the OtCM™ system which measures and monitors patient therapy compliance while interacting wirelessly with home diagnostic devices to correlate compliance with drug therapy.

27 Oct 2011

DSM repurchased 545,760 shares from 13 to 19 October 2011 at an average price of €37.15.

20 Oct 2011

DSM repurchased 391,817 shares from 6 to 12 October 2011 at an average price of €35.51.

13 Oct 2011

DSM repurchased 519,526 shares from 29 September to 5 October 2011 at an average price of €32.42.

06 Oct 2011

DSM acquires Shandong ICD High Performance Fiber Co. Ltd. (ICD), based in Laiwu, Shandong province, China.

30 Sep 2011

DSM updates investment community on progress made with strategy marking the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of ‘the new DSM’.

29 Sep 2011

DSM repurchased 523,199 shares from 22 to 28 September 2011 at an average price of €31.49.

29 Sep 2011

Unsecured credit facility of €500 million is for a minumum term of 5 years and a maximum term of 7 years.

29 Sep 2011

DSM repurchased 404,055 shares from 15 to 21 September 2011 at an average price of €32.52.

22 Sep 2011

On 13 September 2011 a fatal accident took place on DSM property in Augusta (Georgia, USA), in which one contractor lost his life. DSM deeply regrets this tragic accident and expresses its sympathy to the victim’s family.

16 Sep 2011

DSM repurchased 641,065 shares from 7 to 14 September 2011 at an average price of €31.84.

15 Sep 2011

DSM Personalized Nutrition’s corporate wellness business will become part of Viocare’s operations.

13 Sep 2011

DSM once again retained its number one position in the chemical industry sector in the Dow Jones Sustainability World Index.

08 Sep 2011

DSM intends to repurchase 4,000,000 ordinary shares to cover commitments under management and personnel option plans.

07 Sep 2011

Sinochem Group has taken a 50% equity interest in DSM Anti-Infectives for total cash consideration of €210 million on a cash and debt-free basis with 1 January 2011 as effective date.

31 Aug 2011

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 72.338 existing ordinary shares.

24 Aug 2011

Philip Eykerman will join DSM as Executive Vice President Corporate Strategy & Acquisitions.

23 Aug 2011

Q2 EBITDA from continuing operations €339 million, above both Q2 2010 and Q1 2011.

02 Aug 2011

DSM and Nutreco confirm they have decided to jointly explore the possibility to acquire Provimi.

27 Jul 2011

DSM acquires 51% stake in AGI Corporation of Taiwan (AGI), a manufacturer of environmentally friendly UV (ultraviolet) curable resins and other products, through a subscription for newly to be issued shares combined with a public tender offer for about €41 million in total.

12 Jul 2011

Two joint ventures of DSM Engineering Plastics and KA relate to marketing and sales of engineering plastics in Russia and other members of the Commonwealth of Independent States (CIS) and secondly for the production of engineering plastics compounds in a plant located in Togliatti (Russia).

04 Jul 2011

Acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

04 Jul 2011

Acquisition will allow DSM to combine C5 Yeast Company’s business with its own advanced yeast and enzyme technologies for second generation biofuels, further increasing its leadership position in this field.

28 Jun 2011

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 48.077 existing ordinary shares.

24 May 2011

DSM repurchased 264,319 shares from 13 to 16 May 2011 at an average price of €46.56 and concluded the program to repurchase 5,000,000 shares.

17 May 2011

DSM repurchased 502,059 shares from 6 to 12 May 2011 at an average price of €46.05.

13 May 2011

Acquisition allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

10 May 2011

Companies to build a commercial scale plant for the production of bio-based succinic acid, the first non-fossil feedstock derived chemical building block that allows customers in the chemical industry to choose a bio-based alternative with a lower eco-footprint for a broad range of applications.

09 May 2011

DSM repurchased 601,953 shares from 29 April to 5 May 2011 at an average price of €45.78.

06 May 2011

DSM completes sale of DSM Elastomers to LANXESS for €310 million on a cash and debt-free basis.

03 May 2011

DSM has tendered its 4.95% stake in Danisco to DuPont.

02 May 2011

DSM repurchased 435,987 shares from 26 to 28 April 2011 at an average price of €45.33.

29 Apr 2011

DSM declares dividend for 2010 of €1.35 per ordinary share of €1.50 par value.

28 Apr 2011

DSM held its Annual General Meeting of Shareholders on 28 April 2011. Shareholders approved all resolutions on the agenda.

28 Apr 2011

Q1 EBITDA from continuing operations up 14% to €325 million.

27 Apr 2011

DSM intends to appoint Mr. Atzo Nicolaï (1960), currently Member of the Dutch House of Representatives (“Tweede Kamer der Staten-Generaal”) with effect from 1 June 2011.

26 Apr 2011

DSM repurchased 368,294 shares from 15 to 21 April 2011 at an average price of €42.70.

26 Apr 2011

DSM repurchased 326,090 shares from 8 to 14 April 2011 at an average price of €43.53.

15 Apr 2011

DSM repurchased 376,582 shares from 1 to 7 April 2011 at an average price of €43.97.

08 Apr 2011

DSM will implement changes in the presentation of its financial results as from Q1 2011.

08 Apr 2011

DSM repurchased 349,822 of its own shares from 25 to 31 March 2011 at an average price of €43.34.

01 Apr 2011

DSM repurchased 331,532 shares from 18 to 24 March 2011 at an average price of €42.33.

25 Mar 2011

DSM repurchased 479,895 shares from 11 to 17 March 2011 at an average price of €41.13.

18 Mar 2011

DSM repurchased 499,687 shares from 4 to 10 March at an average price of € 43.49.

11 Mar 2011

DSM repurchased 463,780 shares from 24 February to 3 March 2011 at an average price of €42.74.

04 Mar 2011

Partnership with Kemrock Industries in India for the production of specialty composite resins in India.

01 Mar 2011

Acquisition for a total consideration of about €790 million adds new growth platform for healthy and natural food ingredients for infant formula and other food and beverage applications, especially focused on PUFAs such as microbial Omega-3 DHA and Omega-6 ARA.

28 Feb 2011

DSM successfully completes subsequent offering period to its all-cash tender offer to purchase all of the outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

25 Feb 2011

Jinling DSM Resins Co., Ltd. (JDR) will invest approximately €50 million in a new production facility for composite resins in Nanjing, China.

25 Feb 2011

Supervisory Board proposes appointing Mr. Stefan Doboczky to DSM's Managing Board with effect from 1 May 2011.

25 Feb 2011

Q4 operating profit from continuing operations up 17% to €170 million. Full-year operating profit from continuing operations up 74% to €752 million. Dividend increase of 12.5% to €1.35 per ordinary share proposed for 2010.

23 Feb 2011

DSM intends to repurchase 5,000,000 ordinary shares to cover commitments under management and personnel option plans.

23 Feb 2011

DSM Supervisory Board has appointed Rob Routs as its new Chairman.

22 Feb 2011

Tender offer to purchase all of the outstanding shares of common stock of Martek Biosciences Corporation (NASDAQ: MATK), at a price of $31.50 per share, was successful.

21 Feb 2011

Unconditional clearance of the Counsel of the National Competition Commission in Spain for tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

17 Feb 2011

DSM to acquire the majority shareholding in Shandong ICD High Performance Fibre Co Ltd. based in Laiwu, China.

17 Feb 2011

DSM will use new P&L from the publication of the full year 2010 results onwards.

16 Feb 2011

Expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for DSM's offer for all outstanding shares of common stock of Martek Biosciences Corporation (NASDAQ: MATK) at a price of $31.50 per share.

01 Feb 2011

DSM Engineering Plastics to enter two joint ventures with KA.

20 Jan 2011

DSM commences tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

13 Jan 2011

DSM holds a 4.95% stake in Danisco which has been acquired some years ago.

12 Jan 2011

DSM will acquire all the outstanding shares of common stock of Martek for $31.50 in cash per share for total consideration of $1,087 million.

21 Dec 2010

As part of the joint venture agreement, Sinochem Group will take a 50% equity interest in DSM Anti-Infectives for a total cash consideration of €210 million on a cash and debt-free basis.

17 Dec 2010

In accordance with applicable IFRS accounting standards – the remaining impairment of approximately €55 million for DSM Anti-Infectives will be reversed in Q4 2010.

17 Dec 2010

DSM Special Products B.V. sold to Emerald Performance Materials.

16 Dec 2010

DSM agrees sale of the remaining part of DSM Elastomers (DSM Elastomers) to LANXESS for €310 million on a cash and debt-free basis.

14 Dec 2010

Comparative figures as result of divestment of Keltan, and finalized divestment of Thermoplastic Elastomers (Sarlink).

14 Dec 2010

AGI offers a broad range of environmentally friendly UV (ultraviolet) curable resins and other products used in coatings for paper, wood, plastic and graphic arts applications.

08 Dec 2010

DSM Supervisory Board proposes appointing Mrs. Pauline F.M. van der Meer Mohr as member of its Supervisory Board.

08 Dec 2010

DSM continues its number one position in the chemical industry sector in the Dow Jones Sustainability World Index.

04 Nov 2010

Q3 2010 operating profit from continuing operations up 28% to € 185 million (versus € 144 million in Q3 2009). Sales growth from continuing operations 19% compared to Q3 2009. Based on the continued positive business environment, 2010 is expected to be a strong year for DSM.

02 Nov 2010

Comparative figures reflect the reclassification of Citric Acid from the Base Chemicals and Materials cluster to discontinued operations.

02 Nov 2010

Actamax Surgical Materials LLC. to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval.

23 Sep 2010

Ambitious new targets key elements of new strategy, building on Vision 2010, a phase of portfolio transformation.

23 Sep 2010

Intended sale of Citrique Belge is a result of DSM’s ambitions to focus on Life Sciences and Materials Sciences.

23 Sep 2010

Aquisition will allow DSM to incorporate Microbia’s proprietary platform and world class research and development capabilities and support DSM’s ongoing development of the natural carotenoids market.

22 Sep 2010

Sale of Thermoplastic Elastomers (Sarlink®), part of the business group DSM Elastomers, to Teknor Apex agreed.

15 Sep 2010

On Saturday 11 September 2010, a fatal accident took place at the site of DSM in Capua, in which three contractors tragically lost their lives.

12 Sep 2010

Saturday 11 September 2010, a fatal accident took place at the site of DSM in Capua, in which three contractors tragically lost their lives.

11 Sep 2010

DSM once again listed as one of the top leaders in the chemical industry sector in the Dow Jones Sustainability World Index.

09 Sep 2010

Q2 operating profit from continuing operations €246 million (versus €85 million in Q2 2009 and €194 million in Q1 2010). Sales growth from continuing operations 28% compared to Q2 2009. Based on current positive business environment, 2010 is expected to be a strong year for DSM.

03 Aug 2010

Comparative figures reflect the reclassification of DSM Special Products from the Base Chemicals and Materials cluster to discontinued operations.

03 Aug 2010

Innovations will result in greatly improved process economics and productivity for second generation biofuel producers coupled with the sustainability benefits derived from the use of second generation feedstocks.

30 Jun 2010

OCI will start integrating the businesses as of 1 June 2010.

01 Jun 2010

DSM completes acquisition of Mitsubishi Chemical Corporation’s (MCC) Novamid® polyamide business in exchange for DSM’s Xantar® polycarbonate business.

01 Jun 2010

Q1 operating profit from continuing operations €196 million (versus €44 million in Q1 2009 and €149 million in Q4 2009). Organic sales growth from continuing operations +25% compared to Q1 2009. 2010 is expected to be a good year for DSM.

28 Apr 2010

Mrs. Louise Gunning-Schepers will step down as member of the DSM Supervisory Board with effect from 1 September 2010 in connection with her appointment as president of the Health Council of the Netherlands.

01 Apr 2010

An interim dividend of €0.40 per ordinary share having been paid on 28 August 2009, the final dividend for 2009 will amount to €0.80 per ordinary share.

31 Mar 2010

DSM held its Annual General Meeting of Shareholders on 31 March 2010. Shareholders approved all resolutions on the agenda.

31 Mar 2010

Agreement for the sale of DSM Agro and DSM Melamine to OCI for €310 million on a cash and debt-free basis with effect from 1 January 2010.

30 Mar 2010

Comparative figures reflect the reclassification of DSM Agro and DSM Melamine from the Base Chemicals and Materials cluster to discontinued operations.

30 Mar 2010

DSM to acquire MCC’s Novamid® polyamide business in exchange for DSM’s Xantar® polycarbonate business.

26 Feb 2010

DSM ends 2009 with solid Q4 and very strong cash generation. Full year operating profit from continuing operations €370 million. Full year cash flow from operating activities very strong at €1,276 million. Solid financial position − dividend maintained at €1.20 in cash.

24 Feb 2010

DSM Supervisory Board proposes to appoint Mr. Rob Routs as a member.

23 Feb 2010

Agreement to jointly develop a revolutionary coating resin using carbon dioxide as a raw material.

21 Jan 2010

DSM reinforces strong position in markets such as metal packaging (can), pre-painted metal (coil), specialty decorative markets, specialty adhesives, graphic arts and industrial wood.

21 Jan 2010

Shaw Industries and DSM Chemicals North America previously joint venture partners in NPC.

07 Jan 2010

Joint venture agreement for the production, commercialization and market development of bio-based succinic acid, subject to regulatory approvals and notifications.